Paola Queirolo
Paola Queirolo
Istituto Europeo di Oncologia, IRCCS Milano
Verified email at ieo.it
TitleCited byYear
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
7192017
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ...
The lancet oncology 14 (3), 249-256, 2013
5542013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
SJ O'day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ...
Annals of Oncology 21 (8), 1712-1717, 2010
4922010
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
F Belli, A Testori, L Rivoltini, M Maio, G Andreola, MR Sertoli, G Gallino, ...
Journal of Clinical Oncology 20 (20), 4169-4180, 2002
4722002
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity
G Pietra, C Manzini, S Rivara, M Vitale, C Cantoni, A Petretto, M Balsamo, ...
Cancer research 72 (6), 1407-1415, 2012
2262012
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ...
The Lancet Oncology 15 (4), 436-444, 2014
2202014
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
AM Di Giacomo, PA Ascierto, L Pilla, M Santinami, PF Ferrucci, ...
The lancet oncology 13 (9), 879-886, 2012
2122012
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
J Shi, XR Yang, B Ballew, M Rotunno, D Calista, MC Fargnoli, P Ghiorzo, ...
Nature genetics 46 (5), 482, 2014
1972014
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
M Balsamo, F Scordamaglia, G Pietra, C Manzini, C Cantoni, M Boitano, ...
Proceedings of the National Academy of Sciences 106 (49), 20847-20852, 2009
1892009
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Carac˛, ...
Cancer immunology, immunotherapy 63 (7), 675-683, 2014
1662014
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ...
Annals of Oncology 27 (4), 732-738, 2016
1592016
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
E Bajetta, A Di Leo, MG Zampino, MR Sertoli, G Comella, M Barduagni, ...
Journal of clinical oncology 12 (4), 806-811, 1994
1561994
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
R Dummer, D Schadendorf, PA Ascierto, A Arance, C Dutriaux, ...
The Lancet Oncology 18 (4), 435-445, 2017
1472017
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
G Pietra, C Manzini, M Vitale, M Balsamo, E Ognio, M Boitano, P Queirolo, ...
International immunology 21 (7), 793-801, 2009
1322009
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta, M Del Vecchio, P Nova, A Fusi, A Daponte, MR Sertoli, ...
Annals of oncology 17 (4), 571-577, 2006
1302006
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
PA Ascierto, E Simeone, VC Sileni, J Pigozzo, M Maio, M Altomonte, ...
Journal of translational medicine 12 (1), 116, 2014
1262014
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
R Danielli, R Ridolfi, V Chiarion-Sileni, P Queirolo, A Testori, R Plummer, ...
Cancer Immunology, Immunotherapy 61 (1), 41-48, 2012
1162012
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
F Spagnolo, P Ghiorzo, P Queirolo
Oncotarget 5 (21), 10206, 2014
1112014
Radiation‐associated angiosarcoma: Diagnostic and therapeutic implications—Two case reports and a review of the literature
F Cafiero, M Gipponi, A Peressini, P Queirolo, S Bertoglio, D Comandini, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 1996
1091996
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
F Spagnolo, P Ghiorzo, L Orgiano, L Pastorino, V Picasso, E Tornari, ...
OncoTargets and therapy 8, 157, 2015
1082015
The system can't perform the operation now. Try again later.
Articles 1–20